Physician profile
John Lafata
NPI 1285662403
$1,138.67
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $182.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $180.65 | 2019-2020 | |
| Amgen INC. | $158.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $95.88 | 2019-2020 | |
| Novo Nordisk INC | $94.11 | 2019-2020 | |
| Lilly USA, LLC | $90.63 | 2019-2020 | |
| Astellas Pharma US INC | $78.83 | 2019-2020 | |
| Pfizer INC. | $73.21 | 2019 | |
| Merck Sharp & Dohme LLC | $50.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.66 | 2019 | |
| Mannkind Corporation | $21.33 | 2019 | |
| Amarin Pharma, INC. | $20.91 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lafata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.